Skip to main content
SpringerLink
Log in

Loss of ARID1A expression is associated with poor prognosis in patients with stage I/II clear cell carcinoma of the ovary

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Recent studies have shown that somatic mutations in the AT-rich interactive domain 1A (SWI-like) gene (ARID1A) are the most common genetic changes in clear cell carcinoma of the ovary (CCC). A gene mutation of ARID1A was found in approximately half of CCC cases, and led to absence of the encoded protein and inactivation of the putative tumor suppressor. Here, we investigated whether ARID1A could be a prognostic biomarker for this disease.

Methods

We analyzed the protein expression of ARID1A in CCC from 112 patients by immunohistochemical staining, and evaluated the association of these molecular parameters with clinical outcome.

Results

The loss of ARID1A expression was found in 39 % (44/112) of CCC, and was not associated with patient age, FIGO stage, and status of residual tumor. The 5-year survival rate for FIGO stage I or II patients with negative tumor expression of ARID1A was lower than those with positive tumor expression of ARID1A (74 % vs 91 %), but this difference was not observed in FIGO stage III or IV patients. Multivariable analysis revealed that ARID1A expression was an independent prognostic factor in FIGO stage I or II CCC patients.

Conclusion

ARID1A may be a biomarker that is predictive of the outcome of FIGO stage I and II CCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Scully RE (1975) World Health Organization classification and nomenclature of ovarian cancer. Natl Cancer Inst Monogr 42:5–7

    CAS  PubMed  Google Scholar 

  2. Itamochi H, Kigawa J, Terakawa N (2008) Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci 99:653–658

    Article  CAS  PubMed  Google Scholar 

  3. Fukunaga M, Nomura K, Ishikawa E et al (1997) Ovarian atypical endometriosis: its close association with malignant epithelial tumours. Histopathology 30:249–255

    Article  CAS  PubMed  Google Scholar 

  4. Jones S, Wang TL, Shih Ie M et al (2010) Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 330:228–231

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Wiegand KC, Shah SP, Al-Agha OM et al (2010) ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363:1532–1543

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Ho L, Crabtree GR (2010) Chromatin remodelling during development. Nature 463:474–484

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Huang J, Zhao YL, Li Y et al (2007) Genomic and functional evidence for an ARID1A tumor suppressor role. Genes Chromosomes Cancer 46:745–750

    Article  CAS  PubMed  Google Scholar 

  8. Ayhan A, Mao TL, Seckin T et al (2012) Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. Int J Gynecol Cancer 22:1310–1315

    Article  PubMed Central  PubMed  Google Scholar 

  9. Samartzis EP, Samartzis N, Noske A et al (2012) Loss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation? Mod Pathol 25:885–892

    Article  CAS  PubMed  Google Scholar 

  10. Mao TL, Ardighieri L, Ayhan A et al (2013) Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma. Am J Surg Pathol 37:1342–1348

    Article  PubMed Central  PubMed  Google Scholar 

  11. Maeda D, Mao TL, Fukayama M et al (2010) Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma. Int J Mol Sci 11:5120–5128

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Guan B, Mao TL, Panuganti PK et al (2011) Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol 35:625–632

    Article  PubMed Central  PubMed  Google Scholar 

  13. Huang HN, Lin MC, Huang WC et al (2014) Loss of ARID1A expression and its relationship with PI3K–Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma. Mod Pathol 27:983–990

    Article  CAS  PubMed  Google Scholar 

  14. Katagiri A, Nakayama K, Rahman MT et al (2012) Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma. Mod Pathol 25:282–288

    CAS  PubMed  Google Scholar 

  15. Lai CR, Hsu CY, Chen YJ et al (2013) Ovarian cancers arising from endometriosis: a microenvironmental biomarker study including ER, HNF1ss, p53, PTEN, BAF250a, and COX-2. J Chin Med Assoc 76:629–634

    Article  CAS  PubMed  Google Scholar 

  16. Lowery WJ, Schildkraut JM, Akushevich L et al (2012) Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers. Int J Gynecol Cancer 22:9–14

    Article  PubMed Central  PubMed  Google Scholar 

  17. McConechy MK, Ding J, Senz J et al (2014) Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. Mod Pathol 27:128–134

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Wiegand KC, Hennessy BT, Leung S et al (2014) A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation. BMC Cancer 14:120

    Article  PubMed Central  PubMed  Google Scholar 

  19. Wu RC, Ayhan A, Maeda D et al (2014) Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. J Pathol 232:473–481

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Xiao W, Awadallah A, Xin W (2012) Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma. Int J Clin Exp Pathol 5:642–650

    PubMed Central  CAS  PubMed  Google Scholar 

  21. Yamamoto S, Tsuda H, Takano M et al (2012) PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma. Virchows Arch 460:77–87

    Article  CAS  PubMed  Google Scholar 

  22. Wilson BG, Roberts CW (2011) SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 11:481–492

    Article  CAS  PubMed  Google Scholar 

  23. Yokoyama Y, Matsushita Y, Shigeto T et al (2014) Decreased ARID1A expression is correlated with chemoresistance in epithelial ovarian cancer. J Gynecol Oncol 25:58–63

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Wang DD, Chen YB, Pan K et al (2012) Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer. PLoS One 7:e40364

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Cho H, Kim JS, Chung H et al (2013) Loss of ARID1A/BAF250a expression is linked to tumor progression and adverse prognosis in cervical cancer. Hum Pathol 44:1365–1374

    Article  CAS  PubMed  Google Scholar 

  26. Fadare O, Renshaw IL, Liang SX (2012) Does the loss of ARID1A (BAF-250a) expression in endometrial clear cell carcinomas have any clinicopathologic significance? A pilot assessment. J Cancer 3:129–136

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  27. Lichner Z, Scorilas A, White NM et al (2013) The chromatin remodeling gene ARID1A is a new prognostic marker in clear cell renal cell carcinoma. Am J Pathol 182:1163–1170

    Article  CAS  PubMed  Google Scholar 

  28. Yan HB, Wang XF, Zhang Q et al (2014) Reduced expression of the chromatin remodeling gene ARID1A enhances gastric cancer cell migration and invasion via downregulation of E-cadherin transcription. Carcinogenesis 35:867–876

    Article  CAS  PubMed  Google Scholar 

  29. Kuo KT, Mao TL, Jones S et al (2009) Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 174:1597–1601

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2:489–501

    Article  CAS  PubMed  Google Scholar 

  31. Okamoto A, Glasspool RM, Mabuchi S et al (2014) Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary. Int J Gynecol Cancer 24:S20–S25

    Article  PubMed  Google Scholar 

  32. Zang ZJ, Cutcutache I, Poon SL et al (2012) Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet 44:570–574

    Article  CAS  PubMed  Google Scholar 

  33. Bosse T, ter Haar NT, Seeber LM et al (2013) Loss of ARID1A expression and its relationship with PI3K–Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer. Mod Pathol 26:1525–1535

    Article  CAS  PubMed  Google Scholar 

  34. Liang H, Cheung LW, Li J et al (2012) Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res 22:2120–2129

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  35. Samartzis EP, Gutsche K, Dedes KJ et al (2014) Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition. Oncotarget 5:5295–5303

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (17244120 to H. Itamochi).

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Tottori University School of Medicine, 36-1 Nishicho, Yonago, Tottori, 683-8504, Japan

    Hiroaki Itamochi, Nao Oumi, Tetsuro Oishi & Tasuku Harada

  2. Department of Obstetrics and Gynecology, Iwate Medical University, 19-1 Uchimaru, Morioka, Iwate, 020-8505, Japan

    Tadahiro Shoji & Toru Sugiyama

  3. Department of Obstetrics and Gynecology, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan

    Hiroyuki Fujiwara & Mitsuaki Suzuki

  4. Matsue City Hospital, 32-1 Noshira, Matsue, Shimane, 690-8509, Japan

    Junzo Kigawa

Authors
  1. Hiroaki Itamochi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nao Oumi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tetsuro Oishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tadahiro Shoji
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiroyuki Fujiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Toru Sugiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mitsuaki Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Junzo Kigawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tasuku Harada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroaki Itamochi.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Itamochi, H., Oumi, N., Oishi, T. et al. Loss of ARID1A expression is associated with poor prognosis in patients with stage I/II clear cell carcinoma of the ovary. Int J Clin Oncol 20, 967–973 (2015). https://doi.org/10.1007/s10147-015-0811-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-015-0811-x

Keywords

Search

Navigation